课题基金 / 基金详情

RR&D Gordon Mansfield Spinal Cord Injury Consortium

RR&D Gordon Mansfield Spinal Cord Injury Consortium
RR
批准号:
9822285
负责人:
MARK H. TUSZYNSKI
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
未结题
起止时间:
2015-07-01 至 2025-12-31

项目摘要

项目成果

MARK H. TUSZYNSKI的其他基金

相似基金

相关文献

中文摘要
翻译
该项目旨在开发一种神经干细胞(NSC)疗法来修复受伤的脊髓 并支持功能恢复。在拟议的工作中,我们的目标是将这一计划推进到 IND使能阶段。此外,我们的目标是继续开发和优化潜在的干细胞 脊髓损伤(SCI)的治疗--研究创新的康复和治疗的组合 神经干细胞疗法潜在放大的脊髓神经调节策略 干细胞介导的功能恢复。最后,我们的目标是投入大量精力来评估 神经干细胞对慢性脊髓损伤的疗效。 这项工作的重点是从联邦“批准”的人类胚胎干细胞中提取的人类神经干细胞。 细胞(ESC)系,H9 ESC系。我们在这里提出的研究将主要用于临床 相关脊髓损伤、挫伤模型。由外部调查人员独立复制 这个由科学家组成的联盟将进行。 值得注意的是,这是研究脊椎的领先实验室之间密切合作的结果。 脊髓损伤,包括圣地亚哥VA医疗中心和UCSD的Tuszynski组 (包括罗森茨韦格、卢和布罗克博士);圣彼得堡的比蒂/布雷斯纳汉/弗格森组合 旧金山退伍军人医学中心和加州大学旧金山分校;加州大学欧文分校的Reinkensmeyer实验室;哈夫顿实验室 加州大学洛杉矶分校;加州大学戴维斯分校的加州国家灵长类研究中心;以及考廷 瑞士联邦理工学院的实验室。实验是集体设计的 并由该联盟执行,这是SCI研究中前所未有的努力,以推动该领域的发展 通过密切合作和互动,共同开展实验。自始至终,这 该项目将受益于合作者之间的信息自由交流。
英文摘要
This project aims to develop a neural stem cell (NSC) therapy to repair the injured spinal cord and support functional recovery. In the proposed work, we aim to advance this program to an IND-enabling stage. Moreover, we aim to continue to develop and optimize potential stem cell therapies for spinal cord injury (SCI) by examining combinations of innovative rehabilitation and spinal cord neuromodulation strategies with neural stem cell therapies to potentially amplify stem cell-mediated recovery of function. Finally, we aim to invest substantial effort to assess NSC efficacy in chronic SCI. This work focuses on human NSCs derived from a federally “approved” human embryonic stem cell (ESC) line, the H9 ESC line. The studies we propose herein will primarily use clinically relevant spinal cord injury contusion models. Independent replication by an investigator outside this consortium of scientists will be conducted. Notably, this is an intensely collaborative effort among leading laboratories researching spinal cord injury, including the Tuszynski group at the San Diego VA Medical Center and UCSD (includes Drs. Rosenzweig, Lu and Brock); the Beattie/Bresnahan/Ferguson group at the San Francisco VA Medical Center and UCSF; the Reinkensmeyer lab at UC Irvine; the Havton lab at UCLA; the California National Primate Research Center located at UC Davis; and the Courtine lab at the Swiss Federal Institute of Technology. Experiments have been collectively designed and performed by this consortium, an unprecedented effort in SCI research to advance the field through close collaboration and interaction on jointly performed experiments. Throughout, this project will benefit from a free exchange of information among the collaborators.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Advancing human neural progenitor cells (hNPCs) to FDA IND approval
  • 批准号:
    10642228
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2023
  • 负责人:
    MARK H. TUSZYNSKI
  • 依托单位:
The Primate Corticospinal Connectome and Transcriptome - Supplement
A Clinical Trial of AAV2-BDNF Gene Therapy in Alzheimer's Disease
A Clinical Trial of AAV2-BDNF Gene Therapy in Alzheimer's Disease
海外基金